Results 41 to 50 of about 1,978 (184)

Acceptability and use of a dapivirine vaginal ring in a phase III trial [PDF]

AIDS, 2017
The MTN-020/ASPIRE trial evaluated the safety and effectiveness of the dapivirine vaginal ring for prevention of HIV-1 infection among African women. A nested qualitative component was conducted at six of 15 study sites in Uganda, Malawi, Zimbabwe and South Africa to evaluate acceptability of and adherence to the ring.Qualitative study participants (n =
Elizabeth T, Montgomery, Ariane, van der Straten, Miria, Chitukuta, Krishnaveni, Reddy, Kubashni, Woeber, Millicent, Atujuna, Linda-Gail, Bekker, Juliane, Etima, Teopista, Nakyanzi, Ashley J, Mayo, Ariana, Katz, Nicole, Laborde, Cynthia I, Grossman, Lydia, Soto-Torres, Thesla, Palanee-Phillips, Jared M, Baeten   +15 more
openaire   +4 more sources

Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence. [PDF]

AIDS Behav
Product adherence is critical to obtaining objective estimates of efficacy of pre-exposure prophylactic interventions against HIV-1 infection. With imperfect adherence, intention-to-treat analyses assess the collective effects of complete, sub-optimal and non-adherence, providing a biased and attenuated estimate of the average causal effect of an ...
Husnik MJ, Heffron R, Hughes JP, Richardson B, van der Straten A, Palanee-Phillips T, Soto-Torres L, Singh D, Mirembe BG, Livant E, Gaffoor Z, Mansoor LE, Siva SS, Dadabhai S, Kiweewa FM, Baeten JM, MTN-020/ASPIRE Study Team.   +16 more
europepmc   +3 more sources

PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study. [PDF]

J Int AIDS Soc
Abstract Introduction Providing pregnant and lactating people (PLP) with choice in HIV pre‐exposure prophylaxis (PrEP) methods, including long‐acting injectable cabotegravir (CAB‐LA), may mitigate barriers to effective PrEP use. We evaluated PrEP preferences and acceptability among PLP offered CAB‐LA versus oral PrEP in South Africa.
Wara N, Pike C, Rousseau E, Macdonald P, Mapukata P, Leonard B, Lebelo K, Hoffman R, Orrell C, Bekker LG, Davey DJ.   +10 more
europepmc   +2 more sources

Impact of Tenofovir Alafenamide Sub-Dermal Implant Insertion Site Scarring on Acceptability and HIV Prevention Preferences: A Prospective Cohort Study in Durban, South Africa. [PDF]

J Int AIDS Soc
ABSTRACT Introduction The CAPRISA 018 Phase I trial evaluated the safety, tolerability and pharmacokinetics of a 110 mg tenofovir alafenamide (TAF) implant for HIV prevention in South African women. This follow‐up cohort study, CAPRISA 097, assessed the long‐term resolution of implant site reactions (ISRs) after implant removal and explored user ...
Gengiah TN, Lewis L, Harkoo I, Myeni N, Mansoor LE, Karim SSA, Karim QA.   +6 more
europepmc   +2 more sources

Southern African HIV Clinicians Society guideline on pre-exposure prophylaxis to prevent HIV. [PDF]

South Afr J HIV Med
Macdonald P, Macdonald P, Nair G, Wattrus C, Mullick S, Pleaner M, Rousseau E, Subedar H, Joseph-Davey D, Hugo J, Delany-Moretlwe S, Bekker LG.   +11 more
europepmc   +3 more sources

Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa

BMC Women's Health, 2021
Background Clinical trials have found that a monthly dapivirine vaginal ring was well-tolerated and reduced HIV-1 risk among women in sub-Saharan Africa.
Jonah Leslie, Flavia Kiweewa, Thesla Palanee-Phillips, Katherine Bunge, Felix Mhlanga, Betty Kamira, Jared Baeten, Ariana Katz, Sharon Hillier, Elizabeth Montgomery, for the MTN-020/ASPIRE Study Team   +10 more
doaj   +1 more source

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions

Pharmaceutics, 2022
The dapivirine (DPV) vaginal ring was developed by the nonprofit International Partnership for Microbicides (IPM) for reducing the risk of HIV infection.
Ruohui Zheng, Guru R. Valicherla, Junmei Zhang, Jeremy Nuttall, Peter Silvera, Leslie J. Marshall, Philip E. Empey, Lisa C. Rohan   +7 more
doaj   +1 more source

Inhibition of HIV virus by neutralizing Vhh attached to dual functional liposomes encapsulating dapivirine [PDF]

, 2016
Although highly active antiretroviral therapy (HAART) has greatly improved the life expectancy of HIV/AIDS patients, the treatment is not curative.
AF Labrijn, AK Bhatia, BR Starcich, DC Chan, DF Gaddy, DS Watson, E Chertova, EO Freed, G Ofek, GNC Chiu, Guido Vanham, HL Wong, Ivan Roitt, J Cunha Da, J das Neves, J Icenogle, J Liu, Johan Michiels, JP Moore, JS Klein, JS Klein, Kevin K. Ariën, KV1 Rao, L Nieba, LE McCoy, M-Y Zhang, NK Malavia, P Zhu, P Zhu, PD Kwong, PD Kwong, R Clayton, R Duncan, R Wyatt, R Wyatt, RL Shew, Roger New, S Oliveira, Scarlet Xiaoyan Wang, SP Layne, TJ Smith, WWL Koh, X Wei, X Yu   +43 more
core   +1 more source

Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities

AIDS, 2020
Objective: We aimed to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities. Design: Secondary analysis comparing cervical cytology results between two randomized ...
Reddy, Krishnaveni, Kelly, Cliff, Brown, Elizabeth R, Jeenarain, Nitesha, Naidoo, Logashvari, Siva, Samantha, Bekker, Linda-Gail, Nair, Gonasagrie, Makanani, Bonus, Chinula, Lameck, Mgodi, Nyaradzo, Chirenje, Zvavahera, Kiweewa, Flavia Matovu, Marrazzo, Jeanne, Bunge, Katherine, Soto-Torres, Lydia, Piper, Jeanna, Baeten, Jared M, Palanee-Phillips, Thesla   +18 more
openaire   +5 more sources

Dapivirine Vaginal Ring for HIV Prevention in Women in South Africa

Infectious Diseases, 2022
Young women remain disproportionately affected by the HIV epidemic in South Africa. Clinical trials have shown that the dapivirine vaginal ring (DVR) is safe and effective at reducing HIV infection in women. In March 2022, the South African Health Products Regulatory Authority approved the use of the DVR in women aged 18 years and older who are unable ...
Linda-Gail Bekker, Katherine Gill
openaire   +1 more source